论文部分内容阅读
目的观察消癌平注射液联合吉西他滨和卡铂治疗ⅢB和Ⅳ期非小细胞肺癌(NSCLC)的临床疗效。方法选择鄂东医疗集团黄石市中心医院2013年2月—2015年1月治疗的ⅢB和Ⅳ期NSCLC患者106例,随机分为吉西他滨和卡铂化疗对照组与消癌平注射液联合吉西他滨和卡铂化疗观察组,每组53例。比较两组近远期临床疗效以及不良反应。结果治疗4个周期后,观察组的治疗有效率和控制率分别为39.6%和77.4%;对照组的有效率和控制率分别为35.8%和75.5%,两组比较差异无统计学意义。观察组白细胞下降、血红蛋白下降和血小板下降率分别为41.5%、37.7%和45.3%,显著低于对照组的64.2%、62.3%和69.8%(P<0.05)。观察组肾功能损伤、肝功能损伤、恶心、呕吐、头晕、头痛、腹泻和便秘发生率与对照组比较无显著差异。观察组中位生存时间8.4月,肿瘤进展时间5.3个月,1年生存率26.4%;对照组中位生存时间7.7月,肿瘤进展时间4.2个月,1年生存率为11.3%,两组比较差异有统计学意义(P<0.05)。结论消癌平注射液联合吉西他滨和卡铂治疗ⅢB和Ⅳ期NSCLC,可以降低化疗药的血液学毒性,提高远期临床疗效。
Objective To observe the clinical efficacy of Xiao-Jin-Ping injection combined with gemcitabine and carboplatin in the treatment of stage ⅢB and Ⅳ non-small cell lung cancer (NSCLC). Methods Sixty-six patients with stage ⅢB and Ⅳ NSCLC who were treated in Huangshi Central Hospital of East Guangdong Medical Group from February 2013 to January 2015 were randomly divided into gemcitabine and carboplatin-controlled group and Xiaochangping injection combined with gemcitabine and card Platinum chemotherapy observation group, 53 cases in each group. Short-term and long-term clinical efficacy and adverse reactions were compared between the two groups. Results After 4 cycles of treatment, the effective rate and control rate of the observation group were 39.6% and 77.4%, respectively. The effective rate and control rate of the control group were 35.8% and 75.5% respectively. There was no significant difference between the two groups. In the observation group, leukopenia, hemoglobin decrease and platelet decrease rate were 41.5%, 37.7% and 45.3% respectively, which were significantly lower than 64.2%, 62.3% and 69.8% in the control group (P <0.05). The incidence of renal dysfunction, liver injury, nausea, vomiting, dizziness, headache, diarrhea and constipation in the observation group were not significantly different from those in the control group. The median survival time of the observation group was 8.4 months, the tumor progression time was 5.3 months and the 1-year survival rate was 26.4%. The median survival time in the control group was 7.7 months, the tumor progression time was 4.2 months and the 1-year survival rate was 11.3% The difference was statistically significant (P <0.05). Conclusion Xiaojianping injection combined with gemcitabine and carboplatin in the treatment of stage ⅢB and Ⅳ NSCLC can reduce the hematological toxicity of chemotherapy drugs and improve long-term clinical efficacy.